Kornimate/medical-research-clean huggingface dataset:
chlorhexidine gluconate and povidone iodine

Conditions: Evaluate to Effects of Two Antiseptic Products and Showering

Summary: the study was planned to evaluate the effects of two most commonly used antiseptic products and showering on the healing process, such as wound healing and postoperative maternal comfort in cesarean section. a randomized controlled trial included 102 pregnant women from february and may of 2021. they were randomly divided into povidone iodine (pi) group (a) chlorhexidine gluconate (cg) group (b) and cg shower (c) operated by two gynecology and obstetrics physician. data from the in house blinding study to avoid bias and follow-up of the women was done for 7 day duration following postnatal to assess postoperative for comfort, pain, wound complications.

purpose and type of research this study was designed as a randomized controlled trial to examine the effect of preoperative use of cg and pi on the postoperative healing process and maternal postpartum comfort. hypothesis h1: cleaning the incision area with a 2% cg solution (containing 70% alcohol) is more effective in the wound healing process than pi. h2: taking a shower with a 2% cg solution (containing 70% alcohol) 6 hours before, and cleaning the incision area, is more effective in the wound healing process than pi. h3: cleaning the incision area with a 2% cg solution (containing 70% alcohol) produces a higher postpartum comfort level than pi. h4: taking a shower 6 hours before with a 2% cg solution (containing 70% alcohol), and cleaning the incision area, produces a higher postpartum comfort level than pi. variables in the study include dependent variables: signs of the wound healing process at the incision site (erythema, edema, ecchymosis, discharge, wound dehiscence and pain), and independent variables: a 2% cg (70% alcohol) solution and the application of pi. participants this research was carried out in a turkish research hospital clinic between february and may of 2021. the study sample consisted of all pregnant women (n = 504) who were hospitalized with a planned cesarean section scheduled between the study dates. the study sample consisted of 102 pregnant women who met the inclusion criteria and who agreed to participate in the study after informed consent was obtained. they were randomly divided into groups. the study sample consisted of three groups: 1) those cleaned with povidone-iodine (pi) before the surgical incision, 2) those cleaned with chlorhexidine gluconate (cg) before the surgical incision and 3) those showering with cg six hours before the surgical incision and cleaned with cg before the surgical incision.

Eligibility criteria:
inclusion criteria: * hospitalized with a planned cesarean section scheduled between the study dates * volunteer woman exclusion criteria: * participants who dont meet the inclusion criteria * labor

Keywords: cesarean section surgical site infection povidone iodine chlorhexidine gluconate patient comfort healing process
flouro-gem in adenocarcinoma of the pancreas (geflupan)

Conditions: Cancer of Pancreas; Chemotherapy Effect; Metastatic Pancreatic Cancer

Summary: in this study, the investigators designed a treatment regimen including the most active agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first line treatment. this regimen is expected to be less toxic than folfirinox and aiming at better outcomes.

metastatic cancer pancreas has been a challenge for oncologists over the years. it is a disease of limited survival and a very poor response to treatment. the median overall survival at five years is expected to be between 4-6% only. adenocarcinoma is the most common type of pancreatic cancer. it is the tenth most common adult solid malignancy. most of the new therapeutic modalities has proven to be non-beneficial in this disease including targeted and immunotherapy. for many years, the first line of treatment for pancreatic cancer was gemcitabine either alone or in combinations. recently, folfirinox has become the standard of care due to its overall survival benefit. however, it is a small benefit on the expense of great toxicity. patients with metastatic cancer pancreas are recruited to receive the test regimen. baseline evaluation will be done either by ct scan or pet/ct. re-evaluation will be repeated after 3 months of treatment and at end of 6 months

Eligibility criteria:
inclusion criteria: * histopathological evidence of adenocarcinoma of the pancreas * radiological proof of metastatic disease as defined by ajcc exclusion criteria: * patients with poor performance status (ecog 4) * patients with organ dysfunction defined as: creatinine more than 1.6 mg/dl or bilirubin more than 3 mg/dl * patients with end stage renal disease who are under regular dialysis * other histologies of pancreatic cancer * irresectable pancreatic cancer if not metatatic

Keywords: pancreas cancer adenocarcinoma metastatic gemcitabine flourouracil chemotherapy first line
effect of undenatured cysteine-rich whey protein isolate (hms 90®) in patients with parkinson's disease

Conditions: Parkinson Disease; Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Neurodegenerative Diseases

Summary: this is a double-blind, placebo-controlled, phase iv trial , comparing hms 90® versus placebo (soy protein) as add-on (adjuvant) therapy in subjects with idiopathic parkinson's disease. the principal objective is to evaluate the changes in biomarkers of oxidative stress and,plasma amino acids, as well as improvement of clinical symptoms and brain function


Eligibility criteria:
inclusion criteria: 1. subjects with idiopathic parkinson's disease 2. subjects who are willing and able to participate in the trial and has provided written, informed consent. exclusion criteria: 1. subjects who are allergic to whey protein (hms 90®). 2. subjects who are treated with chemotherapy . 3. subjects with any history of neurodegenerative diseases, e.g., alzheimer's disease. 4. subjects with history of diabetes. 4.5. subjects with abnormal liver function test
development in children diagnosed with congenital muscular torticollis

Conditions: Torticollis Congenital; Motor Development; Sensory Integration Dysfunction

Summary: it has been thought that head position may affect the shoulder, rib cage and abdominal muscles, which may have a negative effect on posture control and movement development, sensory-motor coordination and cause retardation in gross motor function. for these reasons, children with congenital muscular torticollis should be evaluated comprehensively in the early period. this study, which was planned to evaluate the motor development and sensory processing of children with torticollis, was designed according to the lack of literature.

congenital muscular torticollis (cmt) is a common postural deformity that occurs shortly after birth and is typically characterized by ipsilateral cervical lateral flexion and contralateral cervical rotation due to unilateral shortening of the sternocleidomastoid (scm) muscle. it is a non-neurological postural disorder that usually affects 3% to 16% of infants. theories such as intrauterine stenosis, vascular causes, fibrosis of the peripartum hemorrhage area, difficult labor, and primary myopathy of the scm muscle have been put forward for its causes. in tissue samples taken after surgery, edema, degeneration of muscle fibers, and fibrosis have been reported. it is thought that cmt affects the muscles as well as head and facial development, causing various asymmetries, delays in gross motor functions, and disorders in posture and balance control. a bent neck position can cause plagiocephaly. characteristic craniofacial deformities include asymmetry in the brow and cheekbones, deviation of the chin and nose tip, inferior orbital abnormality on the affected side, asymmetry in ear placement, and shortening of the vertical dimension of the ipsilateral face. in later periods, it has been shown that it may cause asymmetry in the use of the upper extremities, delay in gross motor functions, and effects on posture and balance control in children. it is thought that head position may affect the shoulder, rib cage, and abdominal muscles, which may have a negative effect on posture control and movement development, sensory-motor coordination, and cause gross motor function retardation. for these reasons, children with congenital muscular torticollis should be evaluated comprehensively in the early period. this study, which was planned to evaluate the motor development and sensory processing of children with cmt, was designed according to the lack of literature.

Eligibility criteria:
inclusion criteria: * infants diagnosed with congenital torticollis between 0-12 months of age, * with parental consent, exclusion criteria: * children with chromosomal abnormalities, * serious congenital problems, * vision-hearing problem * children whose parents do not volunteer for the study will not be included in the study.

Keywords: torticollis motor development sensory processing skills infant
clinical effects in cervical spinal mobilization and oscillation mobilization in neck pain

Conditions: Manual Therapy; Neck Pain

Summary: the aim of this study is to compare the clinical effects of spinal mobilization versus vertebral resonant oscillation (pold) in patients with bilateral mechanical neck pain on pain sensitivity and neck pain intensity.

the clinical practice guidelines for manual therapy management the neck pain including the spine mobilization. the vertebral resonant oscillation using the pold method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 hz and the amplitude is similar to "neutral zone" to described by panjabi 1992. the spinal mobilizations has a posterior-anterior vertebral movement for spinous process, described by maitland 2000.

Eligibility criteria:
inclusion criteria: * neck pain symptoms of mechanical nature * age from 18 to 60 years * bilateral symptoms * symptoms for at least 3 month of duration exclusion criteria: * whiplash injury * previous spine surgery * diagnosis of cervical radiculopathy or myelopathy * having undergone any physical therapy intervention in the previous 6 month * pregnancy

Keywords: mobilization resonant oscillation
measure of the long term influence of spiriva® in acute respiratory disorders

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the objectives of this study were to evaluate the effect of a one-year treatment with inhaled tiotropium bromide 18 mcg once daily on lung function, incidence and severity of exacerbations in patients with chronic obstructive pulmonary disease (copd). the secondary purpose was to explore possible relationships between lung function changes and occurrence of copd exacerbations and to try to characterize these exacerbations.

this was a multicentre, randomised, double blind, parallel group, placebo-controlled, one year study. it was designed to determine the effect of inhaled tiotropium treatment on airflow obstruction (pefr), incidence and severity of exacerbations in patients with copd. following an initial 3-week screening period qualifying patients were randomized to either tiotropium or placebo at visit 2. patients returned to the clinic at weeks 6 (visit 3), 12 (visit 4), 24 (visit 5), 36 (visit 6), 48 (visit 7) and at week 50 for the conclusion of the trial (visit 8). the patients received treatment daily for 48 weeks (336 days). pefr, as well as use of rescue medication and respiratory condition, were self-assessed by patients and recorded every morning on a graphical diary card every morning. the graphical presentation of these data was supposed to help investigators to detect exacerbations occurring between two consecutive visits. details on hospitalizations due to copd exacerbations were recorded in a special hospitalization booklet. study hypothesis: the objectives of this study were to evaluate the effect of a one-year treatment with inhaled tiotropium bromide 18 mcg once daily on lung function, incidence and severity of exacerbations in patients with chronic obstructive pulmonary disease (copd). the secondary purpose was to explore possible relationships between lung function changes and occurrence of copd exacerbations and to try to characterize these exacerbations. comparison(s): tiotropium 18 mcg once daily vs placebo

Eligibility criteria:
* diagnosis of copd according to the european respiratory society (ers) (r95-3225) and matching the following criteria: * stable moderate to severe airway obstruction * baseline 30 % \< fev1 \< 65 % of european community of coal and steel (eccs) predicted values (r94-1408). * baseline fev1/svc\< 70 %. * smoking history \> 10 pack-years (p.y.). a p.y. was defined as the equivalent of smoking * one pack of cigarettes per day for one year. * history of exacerbation in the past year.
tdm of asparaginase in all2008

Conditions: Acute Lymphoblastic Leukemia

Summary: asparaginase is a cornerstone in the treatment of all. in most contemporary protocols like in nopho all2008 prolonged asparaginase treatment has been implemented. publish data from nopho all2008 show sufficient treatment of the majority of patients (analysing trough levels of asparaginase after 2 weeks) but 13% of the patients experience an allergic reaction to this foreign protein (85% of them after the 2nd or 3rd dose) and they have no enzyme activity even before the reaction, meaning that they don't benefit from the treatment at all. in addition 4-5% of the patients have no enzyme activity through the whole treatment without hypersensitivity symptoms. so in reality approximately 20% of the patients don't receive any asparaginase treatment. therapeutic drug monitoring (tdm) of asparaginase has been established in aarhus, denmark, under the leadership of birgitte klug albertsen (bka). from february 2017 the centers have been invited to send samples (extended sampling) in order to gain more knowledge about the pharmacokinetics, to identify patients without activity and to establish the logistics for tdm of asparaginase, which will be mandatory in the next protocol alltogether, presumably opening in 2018. from february 2016 an extended sampling for enzyme activity measurements was started and will continue until nopho all2008 closes. these samples will make it possible to do more in depth pharmacokinetic studies as well as identify the optimal sampling time points for identifying no-activity patients in the future. a database is being developed for tdm in alltogether, but it will also include all the asparaginase measurements in all2008.


Eligibility criteria:
inclusion criteria: * all treated on the nopho all2008 protocol, age 1-45 years. exclusion criteria: * no samples sent
vitamin d deficiency and postoperative hypocalcemia

Conditions: Hypocalcemia

Summary: hypocalcemia is a frequent adverse event after thyroidectomy. it is usually related to hypoparathyroidism, but preoperative hypocalcemia, hypomagnesemia or vitamin d deficiency contributes to it. this study aims to determine the frequency of vitamin d deficiency or insufficiency in patients submitted to thyroidectomy, to define the risk attributed to vitamin d deficiency to postoperative hypocalcemia, to identify other factors associated to postoperative calcium disorder, and to evaluate the benefit of preoperative treatment of vitamin d deficiency to prevent postoperative hypocalcemia.

subjects to be submitted to total thyroidectomy will be included in the study. the investigators will evaluate serum levels of total calcium, ionic calcium, phosphorus, magnesium, creatinine, albumin, alkaline phosphatase, fasting glucose, thyroid stimulating hormone (tsh), free thyroxin (ft4), intact parathyroid hormone (pth), 25 hydroxy vitamin d (25ohd), osteocalcin, c-terminal telopeptide (ctx) and procollagen type 1 amino-terminal propeptide (p1np). patients will be randomized to 3 groups: (1) 30 subjects with 25ohd \ = 20 ng/ml that will not receive cholecalciferol before surgery. afterwards, the investigators will evaluate immediate postoperative pth and measure serum levels of total calcium, ionic calcium, magnesium, alkaline phosphatase, osteocalcin, ctx and p1np in first and second postoperative days for further analysis.

Eligibility criteria:
inclusion criteria: * patients that will be submitted to total thyroidectomy exclusion criteria: * \< 18 year-old * chronic renal failure (creatinine \> 1.5 mg/dl) * fasting glucose \> 200 mg/dl * albumin \< 3.5 g/l * preoperative use of calcium supplements, bisphosphonates, corticosteroids

Keywords: hypocalcemia vitamin d deficiency cholecalciferol thyroidectomy
extension study of agt-181-102 to evaluate long term safety and activity of agt-181

Conditions: Mucopolysaccharidosis I

Summary: agt-181 is a fusion protein containing alpha-l-iduronidase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously. this study is an extension of a safety and dose ranging study to obtain long term safety and exposure data, as well as information on the biological activity of the investigational drug


Eligibility criteria:
inclusion criteria: * must have completed clinical trial agt-181-102 * voluntary written consent by patient or legally responsible representative * all women of childbearing potential and sexually mature males must be advised to use a medically accepted method of contraception throughout the study. * negative pregnancy test (females) exclusion criteria: * refusal to complete screening evaluations. * any medical condition or other circumstances that may significantly interfere with study compliance * patient is pregnant or lactating * clinically significant spinal cord compression, evidence of cervical instability. * subject developed clinically relevant hypersensitivity to agt-181
study of aripiprazole in patients with bipolar i disorder with a major depression episode

Conditions: Bipolar Disorder

Summary: the purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.


Eligibility criteria:
* ages 18-65 * men and women, who have experienced a prior manic episode that required hospitalization, and now meet criteria for a major depressive episode.

Keywords: bipolar 1 disorder, depressed
a study of ly3461767 in participants with chronic heart failure with reduced ejection fraction

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Summary: the main purpose of this study is to determine the tolerability and safety of ly3461767 with any side effects that might be associated with it. study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. blood tests will be performed to check concentrations of ly3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (hfref). the study will last up to 3 months and may include 5 visits.


Eligibility criteria:
inclusion criteria: * are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential * have a body mass index (bmi) of \</= 45.0 kilograms per square meter (kg/m²) * have chronic stable heart failure (new york heart association (nyha) classification ii and iii) on guideline directed heart failure therapy for at least 6 months prior to enrolment * have not changed optimal guideline directed therapy in the last 1 month prior to screening, if treated with oral diuretics, dose must be stable for at least 2 weeks prior to screening * have left ventricular ejection fraction (lvef) \< 40% * have a record of n-terminal pro b-type natriuretic peptide (nt-probnp) ≥ 200 picograms per millilitre (pg/ml) or a bnp value of \>/= 60 pg/ml within the past 12 months prior to screening exclusion criteria: * have myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke in the last 90 days prior to screening * have acute decompensated heart failure requiring iv diuretics within 12 weeks prior to screening * have cardiac amyloidosis, accumulation diseases (e.g., haemochromatosis, fabry disease), muscular dystrophies, hypertrophic cardiomyopathy, pericardial constriction, or complex congenital heart disease. * have any moderate-to-severe stenosis of the mitral and/or aortic valve or moderate-to severe or greater mitral and/or aortic regurgitation. * have a history or presence of hepatic, pancreatic, or biliary tract disorders * have a history of malignancy or active malignancy at screening. * have not had age-appropriate cancer screening as recommended by the american cancer society and per medical judgment

Keywords: heart failure
indirect comparison between eltrombopag & romiplostim

Conditions: Thrombocytopaenia

Summary: an indirect comparison to compare the efficacy of eltrombopag versus romiplostim

an indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator

Eligibility criteria:
inclusion criteria: * adults with itp * pre-specified treatment * prospective clinical studies with at least 10 patients exclusion criteria: * adults with itp for other reasons
breakfast nutrition and inpatient glycemia

Conditions: Diabetes, Type 1; Diabetes, Type 2; Cardiovascular Disease; Hyperglycemia

Summary: a standard hospital meal often contains a high percentage of carbohydrates (cho), which may not be ideal for patients with diabetes. this concern is particularly pertinent to the breakfast meal, which often contains mainly cho. clinical observations suggested that such diets elevate pre-lunch blood glucose (bg) values. the study team compared standard hospital "no concentrated sweets (ncs)" breakfast meals with more balanced meals. the study team hypothesized that a balanced breakfast would improve pre-lunch bg values. this 8-week pilot study was conducted at duke hospital on two non-icu cardiology wards. ward a consisted mainly of patients with a primary diagnosis of coronary artery disease (cad). ward b consisted mainly of patients with a primary diagnosis of congestive heart failure (chf). the intervention breakfast menu included 5 choices containing 40-45g of cho. all patients on ward a (with and without diabetes) were given the intervention breakfast for the first 4 weeks of the study, while those on ward b received standard menus (60-75g cho in ncs meals). after 4 weeks, the standard and intervention wards were switched. data were collected only on patients with diabetes who were able to consume meals.


Eligibility criteria:
inclusion criteria: * adults with cardiovascular disease who were admitted to 2 pre-specified wards at duke medical center during the study period * diagnosis of diabetes (type 1 or 2) or newly identified hyperglycemia (blood glucose of \>200 on 2 separate occasions) * able to consume food by mouth exclusion criteria: * intensive care patients * no intake by mouth (enteral, parenteral, npo) * taking in nutrition supplements (ensure, etc)

Keywords: inpatient diabetes inpatient diabetes nutrition